Third Harmonic Bio

Biotech · Defunct

KIT receptor inhibitor small molecule (THB001) for mast cell-driven diseases

thirdharmonicbio.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
17
2 granted · 15 pending
Sector median: 2

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1268Monte Rosa Therapeutics, Inc.—$143M
1269Tyra Biosciences, Inc.—$200M
1270NEUROEPIGENIX, LLC——
1271Third Harmonic Bio——
1272BridgeBio Oncology Therapeutics——
1273Beam Therapeutics—$180M
1274SYNSPIRA THERAPEUTICS, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 2 granted of 17
  • Crystalline Forms Of A Selective C-kit Kinase Inhibitorgranted
  • Pharmaceutical Compositions Of A Selective C-kit Kinase Inhibitor And Methods For Making And Using Samegranted
  • Compounds And Compositions As C-kit Kinase Inhibitorsapplication
  • Compounds And Compositions As C-kit Kinase Inhibitorsapplication
  • COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORSapplication
  • Compounds And Compositions As C-kit Kinase Inhibitorsapplication
  • Compounds And Compositions As C-kit Kinase Inhibitorsapplication
  • Methods For Treating C-kit Kinase Mediated Diseases And Disorders Using A Selective C-kit Kinase Inhibitorapplication
  • Pharmaceutical Compositions Of A Selective C-kit Kinase Inhibitor And Methods For Making And Using Sameapplication
  • Methods For Treating C-kit Kinase Mediated Diseases And Disorders Using A Selective C-kit Kinase Inhibitorapplication
  • Pharmaceutical Compositions Of A Selective C-kit Kinase Inhibitor And Methods For Making And Using Sameapplication
  • Crystalline Forms Of A Selective C-kit Kinase Inhibitorapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.